Chester Drum, M.D. Ph.D., is an assistant professor at the National University of Singapore, a consultant cardiologist at the National University Hospital and director of the clinical trial innovation lab at TLGM, A*STAR. He is a Singapore permanent resident and currently maintains both internal medicine and cardiology board certifications in the US and Singapore. Dr. Drum received an M.D. and Ph.D. from the University of Chicago. He was trained in medicine at the University of California, San Diego and as a cardiologist at Brigham and Women’s Hospital (Harvard Medical School), in Boston. He then moved to Massachusetts Institute of Technology (MIT) where he was director of translational medicine for the regulatory innovation group, MIT-NEWDIGS. While at MIT, he received the Burroughs Wellcome Career Award for Medical Scientists. In Singapore, he has been a recipient of a Clinician Scientist Award from the NMRC.

Dr. Drum’s current research centers on mass spectroscopy for precision medicine and clinical trial design. Specifically, the lab focuses on new forms of novel biomarker detection and multi-omics analyses of large patient cohorts. As a practicing consultant, Dr. Drum oversees trial design, patient recruitment, pre-analytical protocol development and both quantitative and high-resolution mass spectroscopy technique development and validation. A central thrust of the research program is to define critical unmet in established clinical workflows uniquely suited for LCMS technology. Dr. Drum currently oversees 7 active IRB protocols, three SMART innovation awards and is currently the primary investigator on a multimillion dollar, multi-institutional, 3,000 person clinical trial in Singapore. He has served as a contributing editor to Science Translational Medicine, is appointed as a domain expert for the Singapore Precision Medicine initiative, holds an active MOU with Agilent Corporation and currently sits on the Board of Directors, Asian Scientist Publishing.